This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioPlus Acquisition Stock (NASDAQ:BIOS) 30 days 90 days 365 days Advanced Chart Get BioPlus Acquisition alerts:Sign Up Key Stats Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,636 shsAverage Volume122,781 shsMarket Capitalization$209.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York. Read More Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOS Stock News HeadlinesUpstream Bio Pursues $100 Million IPO Plan With Encouraging Trial ResultsSeptember 25, 2024 | seekingalpha.comPayMate Plans to Acquire DigiAsia BiosSeptember 24, 2024 | marketwatch.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 11 at 2:00 AM | Porter & Company (Ad)Gigabyte details BIOS roll-out plan to neutralize Sinkclose vulnerability — eligible AMD CPUs should be patched by end of the monthAugust 24, 2024 | yahoo.comMadison's Mirus Bio to be acquired by MilliporeSigma for $600 millionMay 28, 2024 | bizjournals.comBiogen enters deal to acquire HI-Bio for $1.8bnMay 23, 2024 | msn.comBiogen’s Strategic Acquisition of HI-Bio and Diversification into Orphan Drug Market Prompt ‘Buy’ RatingMay 22, 2024 | markets.businessinsider.comBiogen to buy San Francisco startup developing a drug for kidney disease for $1.2BMay 22, 2024 | bizjournals.comSee More Headlines BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an IPO on Friday, December 3rd 2021. The company issued 18,000,000 shares at $10.00 per share. Cantor served as the underwriter for the IPO. What other stocks do shareholders of BioPlus Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPlus Acquisition investors own include TransMedics Group (TMDX), Deciphera Pharmaceuticals (DCPH) and BioMarin Pharmaceutical (BMRN). Company Calendar Today7/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.10 million OptionableNot Optionable Beta0.01 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:BIOS) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPlus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
